The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays

Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.

In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing. This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.

Presenter: Blaine Roberts, PhD (Associate Professor, Department of Biochemistry and Department of Neurology, Emory University)

Dr. Blaine Roberts is an Associate Professor In the Department of Biochemistry and Department of Neurology at Emory University. He obtained his Bachelor of Science in Chemistry at Montana State University and his PhD in Biochemistry and Biophysics from Oregon State University. His research group focuses on using protein biochemistry and mass spectrometry to understand Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis. He has interest in understanding the role of metals in biology and has developed new proteomic technologies to measure metalloproteins. Further, his group is using proteomics to characterize new blood borne biomarkers for Alzheimer’s and Parkinson’s disease.